Genetic clonal diversity predicts progression to esophageal adenocarcinoma.

PubWeight™: 6.71‹?› | Rank: Top 1%

🔗 View Article (PMID 16565718)

Published in Nat Genet on March 26, 2006

Authors

Carlo C Maley1, Patricia C Galipeau, Jennifer C Finley, V Jon Wongsurawat, Xiaohong Li, Carissa A Sanchez, Thomas G Paulson, Patricia L Blount, Rosa-Ana Risques, Peter S Rabinovitch, Brian J Reid

Author Affiliations

1: The Wistar Institute, 3601 Spruce St., Philadelphia, Pennsylvania 19104, USA. cmaley@alum.mit.edu

Articles citing this

(truncated to the top 100)

Clonal evolution in cancer. Nature (2012) 11.07

Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24

Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48

Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82

Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90

Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet (2014) 3.75

Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45

Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ (2010) 3.44

Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep (2014) 3.24

ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol (2015) 3.22

Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56

Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut (2008) 2.51

Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med (2015) 2.48

Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet (2017) 2.42

Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40

Emergence of spatial structure in cell groups and the evolution of cooperation. PLoS Comput Biol (2010) 2.35

Colorectal cancer molecular biology moves into clinical practice. Gut (2010) 2.32

Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep (2012) 2.28

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23

Single-cell mutational profiling and clonal phylogeny in cancer. Genome Res (2013) 2.10

Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10

History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 2.04

Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99

Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med (2015) 1.98

Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res (2009) 1.91

Clinical implications and utility of field cancerization. Cancer Cell Int (2007) 1.91

A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89

Divergent clonal selection dominates medulloblastoma at recurrence. Nature (2016) 1.81

Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov (2014) 1.69

An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58

Tracing the tumor lineage. Mol Oncol (2010) 1.56

The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila) (2010) 1.55

Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50

Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47

Selection and adaptation during metastatic cancer progression. Nature (2013) 1.46

High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer (2013) 1.43

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) (2008) 1.43

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.38

Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38

Cancer evolution: mathematical models and computational inference. Syst Biol (2014) 1.36

Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35

Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLoS One (2011) 1.32

MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol (2012) 1.31

Intratumor heterogeneity in evolutionary models of tumor progression. Genetics (2011) 1.31

Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31

Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer. Proc Natl Acad Sci U S A (2015) 1.26

Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. Cancer Res (2015) 1.26

Intra-tumor heterogeneity of MLH1 promoter methylation revealed by deep single molecule bisulfite sequencing. Nucleic Acids Res (2009) 1.26

Evolutionary foundations for cancer biology. Evol Appl (2013) 1.25

Cancer research meets evolutionary biology. Evol Appl (2009) 1.24

Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci U S A (2015) 1.24

Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis (2007) 1.23

Evolution of the cancer genome. Trends Genet (2012) 1.22

Modeling somatic evolution in tumorigenesis. PLoS Comput Biol (2006) 1.22

Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21

Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput Biol (2014) 1.21

Evolutionary determinants of cancer. Cancer Discov (2015) 1.19

Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors. PLoS Comput Biol (2011) 1.18

Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med (2014) 1.18

Cancer in light of experimental evolution. Curr Biol (2012) 1.17

Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15

Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 1.15

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget (2015) 1.15

Evolutionary dynamics of intratumor heterogeneity. PLoS One (2011) 1.14

Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. Br J Cancer (2010) 1.13

Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) (2010) 1.12

MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest (2015) 1.12

APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discov (2015) 1.10

Dpp signaling determines regional stem cell identity in the regenerating adult Drosophila gastrointestinal tract. Cell Rep (2013) 1.09

Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer (2017) 1.07

Evolutionary game theory of growth factor production: implications for tumour heterogeneity and resistance to therapies. Br J Cancer (2013) 1.07

Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 1.06

Evolutionary dynamics of tumor progression with random fitness values. Theor Popul Biol (2010) 1.05

The role of genetic diversity in cancer. J Clin Invest (2010) 1.05

Modelling the evolution of genetic instability during tumour progression. Evol Appl (2012) 1.04

Simulating Brain Tumor Heterogeneity with a Multiscale Agent-Based Model: Linking Molecular Signatures, Phenotypes and Expansion Rate. Math Comput Model (2009) 1.04

Targeted endoscopic imaging. Gastrointest Endosc Clin N Am (2009) 1.03

Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS One (2012) 1.03

Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol (2013) 1.02

Hypermutable DNA chronicles the evolution of human colon cancer. Proc Natl Acad Sci U S A (2014) 1.02

Spatial structure increases the waiting time for cancer. New J Phys (2011) 1.02

A cellular isolation system for real-time single-cell oxygen consumption monitoring. J R Soc Interface (2008) 1.01

Epigenetic biomarkers in esophageal cancer. Cancer Lett (2012) 1.01

Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One (2012) 0.99

The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model. Biol Direct (2010) 0.97

Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol (2009) 0.97

Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer (2014) 0.97

Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther (2013) 0.96

New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management. Clin Cancer Res (2011) 0.96

NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant (2010) 0.95

Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. Int J Cancer (2009) 0.94

Targeting the adaptability of heterogeneous aneuploids. Cell (2015) 0.93

Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov (2015) 0.93

DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses. Epigenetics (2011) 0.93

Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res (2015) 0.93

Articles by these authors

Extension of murine life span by overexpression of catalase targeted to mitochondria. Science (2005) 10.11

Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33

Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest (2009) 5.66

mTOR is a key modulator of ageing and age-related disease. Nature (2013) 5.40

High frequency targeted mutagenesis in Arabidopsis thaliana using zinc finger nucleases. Proc Natl Acad Sci U S A (2010) 4.78

Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet (2007) 3.53

mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science (2013) 3.41

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27

Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistance. Cell Metab (2010) 3.07

Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2007) 3.00

Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res (2011) 2.99

Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation (2009) 2.96

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84

DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet (2008) 2.77

Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS Med (2005) 2.72

Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40

Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol (2011) 2.40

Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 2.39

Transcription activator-like effector nucleases enable efficient plant genome engineering. Plant Physiol (2012) 2.36

Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc Natl Acad Sci U S A (2009) 2.33

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23

DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol (2003) 2.22

Gene expression analyzed by high-resolution state array analysis and quantitative proteomics: response of yeast to mating pheromone. Mol Cell Proteomics (2004) 2.22

Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15

Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res (2004) 2.15

Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology (2008) 2.14

Mitochondria and tumor progression in ulcerative colitis. J Natl Cancer Inst (2013) 2.09

Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet (2002) 2.08

Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med (2012) 1.98

Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea (2009) 1.96

A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89

Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. J Gerontol A Biol Sci Med Sci (2008) 1.83

The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res (2004) 1.76

MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci U S A (2010) 1.73

A likelihood-based approach to mixed modeling with ambiguity in cluster identifiers. Biostatistics (2008) 1.72

Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc Natl Acad Sci U S A (2009) 1.69

A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67

Lethal mitochondrial cardiomyopathy in a hypomorphic Med30 mouse mutant is ameliorated by ketogenic diet. Proc Natl Acad Sci U S A (2011) 1.59

Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell (2004) 1.57

Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2010) 1.55

Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52

Retracted Alteration of astrocytes and Wnt/β-catenin signaling in the frontal cortex of autistic subjects. J Neuroinflammation (2012) 1.51

Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues. Anal Chem (2006) 1.49

Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. Trends Cardiovasc Med (2009) 1.48

Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. Hum Mol Genet (2006) 1.48

Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47

Age-dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria. Aging Cell (2010) 1.47

Mitochondria and cardiovascular aging. Circ Res (2012) 1.46

Disruption of protein kinase A in mice enhances healthy aging. PLoS One (2009) 1.43

Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) (2008) 1.43

Telomere length in the colon declines with age: a relation to colorectal cancer? Cancer Epidemiol Biomarkers Prev (2006) 1.42

Alginate production by Pseudomonas putida creates a hydrated microenvironment and contributes to biofilm architecture and stress tolerance under water-limiting conditions. J Bacteriol (2007) 1.41

Cardiac aging: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal (2012) 1.40

An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence. Nat Immunol (2010) 1.39

Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer. Am J Pathol (2002) 1.39

Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis (2003) 1.39

Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol Ther (2009) 1.37

Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res (2008) 1.36

Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am (2003) 1.36

Accelerated telomere shortening and replicative senescence in human fibroblasts overexpressing mutant and wild-type lamin A. Exp Cell Res (2007) 1.36

Werner syndrome diploid fibroblasts are sensitive to 4-nitroquinoline-N-oxide and 8-methoxypsoralen: implications for the disease phenotype. FASEB J (2002) 1.35

Functional role of the Werner syndrome RecQ helicase in human fibroblasts. Aging Cell (2007) 1.32

Molecular mechanisms underlying genotype-dependent responses to dietary restriction. Aging Cell (2013) 1.31